API reference
Alfuzosin
- CAS number
- 81403-80-7
- Molecular formula
- C19H27N5O4
- Molecular weight
- 389.4 g/mol
About this molecule
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
- InChIKey
- WNMJYKCGWZFFKR-UHFFFAOYSA-N
- SMILES
- CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
- Other CAS numbers recorded
- 1100050-87-0
- PubChem CID
- 2092
Also known as
alfuzosin · Alfuzosina · Alfuzosine · Alfuzosinum · alphuzosine · alfusozine · G04CA01 · Alfuzosin (INN)
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.